主页 > 医学新闻 >
【medical-news】cox－2的过表达可预示前列腺癌进程
Study first: Over-expression of Cox-2 can predict prostate cancer outcome
Researchers say an over-expression of COX-2 in men with prostate cancer is associated with an increase in PSA after radiation treatment and the spread of the cancer outside of the prostate. That is the result of the first study linking COX-2 (cyclooxygenase-2) with prostate cancer radiation treatment outcomes. The study, sponsored by the Radiation Therapy Oncology Group (RTOG 92-02), was presented today at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Philadelphia by Li-Yan Khor, M.D., a fellow in the Radiation Oncology Department at Fox Chase Cancer Center in Philadelphia.
"We found that an increased level of COX-2 prior to treatment was linked with biochemical failure and distant metastasis but was not predictive of overall survival," explained Khor.
For the study, Khor and colleagues analyzed 586 cases from RTOG 92-02 which had available tissue and suitable staining by immunohistochemistry. Median follow-up was 106.9 months. The intensity of COX-2 staining was quantified by automated image analysis provided by a commercial company.
The 5 year distant metastasis rate was 10.6 percent for a COX-2 intensity score less than 134, versus 14.1 percent for an intensity score greater than 134. A high intensity of COX-2 also predicted biochemical failure, the immediate PSA rise after treatment.
Khor added that data from animals have shown that inhibition of COX-2 suppresses angiogenesis (development of blood vessels) and the growth of prostate cancer, and is believed to make the cancer cells more sensitive to radiation therapy.
"This research suggest the need to know more about the levels of COX-2 in our patients," says Khor. "If men show increased levels of COX-2 perhaps radiation treatment will follow an attempt to inhibit COX-2 expression thereby making their cancer more responsive to radiation therapy."
Khor adds "Future studies in this area should include additional biopsy information to determine if COX-2 over-expression is associated with the inability to completely eliminate the cancer within the prostate." 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 cox－2的过表达可预示前列腺癌进程
研究者报道:在男性前列腺癌患者中一个过度表达的Cox-2与放疗后及前列腺以外癌中的前列腺特异抗原的增加相关.这促使了最新的研究COX-2(环氧化酶2)与前列腺癌放射疗法的结合.这项研究,是由放射疗法的肿瘤学团体(RTOG 92-02)发起的.它已在费城一年一次召开的美国社会关于放射治疗学和肿瘤学的第48次会议中被Li-Yan Khor, M.D.提及,他是费城 Fox Chase癌症中心 放射肿瘤学部门的会员.
Khor解释道：“我们发现较早增加的的COX-2水平与治疗的生化紊乱与远端转移与预测总生存数不否。
在这项研究中，Khor和他的同事分析了586例用免疫组织化学染色的有用组织的RTOG 92-02。
在随后的106.9个月中间，用商业公司提供的自动图象分析系统对COX-2染色强度定量分析。
10.6%五年远端转移率在COX-2亮度分数不超过134，而14.1%五年远端转移率的亮度分数超过了134。COX-2的高强度也预示着治疗后的生化紊乱与PSA水平升高。
Khor也从动物实验数据得出抑制COX-2就能抑制血管发生与抑制前列腺癌的生长，而且使得癌细胞对放疗更加敏感。
Khor说：“这项研究提示我们要更加了解病人体内的COX-2水平，如果病人的COX-2的水平持续升高，我们就要在放疗后进行抑制COX-2表达的治疗以使癌症对放疗更敏感。
Khor补充道：“将来在这个领域里的研究应该包括活组织检查情况以确定COX-2的过度表达是否与全面的杀伤癌细胞包括前列腺癌所产生的抑制有关。” [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-07-10 17:31
医学,生命科学网